Lessons learned from a cancer knowledge translation grants program: results of an evaluation.

Knowledge translation capacity building grant competitions integrated knowledge translation

Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
08 2019
Historique:
entrez: 25 9 2019
pubmed: 25 9 2019
medline: 15 5 2020
Statut: ppublish

Résumé

A novel way to build capacity in knowledge translation (kt) is through kt-focused grant competitions. Since 2009, the Knowledge Translation Research Network (KT-Net) has had a cancer-related kt grants program. We undertook an evaluation of the program to determine if KT-Net was achieving its aims of building capacity in cancer kt, advancing the science of kt, building partnerships, and leveraging funding. An adapted framework guided the evaluation. Nine funded studies from 4 competitions were included. Semi-structured telephone interviews were held with researchers, stakeholders (including knowledge users), members of grant review panels, and experts in kt. Interview transcripts were audio-recorded, transcribed, and analyzed thematically. A review of proposal and report documents was also conducted. Funded researchers indicated that the grant competition was an essential funding program for cancer kt research. Competitions were perceived to build capacity in cancer kt among early-career researchers and to encourage innovative cancer kt research for which alternative funding sources are limited. The grants program resulted in incremental gains in advancing the science of kt. Suggestions to improve the program included stronger partnerships between the funder and the provincial cancer-system organization to optimize the application of research that is relevant to the organization's strategic objectives. The grants program met many of its aims by providing cancer researchers with an opportunity to gain capacity in cancer kt and by making incremental advances in kt science. Suggestions to improve the program included closer partnerships between the funder and the cancer-system organization.

Sections du résumé

Background
A novel way to build capacity in knowledge translation (kt) is through kt-focused grant competitions. Since 2009, the Knowledge Translation Research Network (KT-Net) has had a cancer-related kt grants program. We undertook an evaluation of the program to determine if KT-Net was achieving its aims of building capacity in cancer kt, advancing the science of kt, building partnerships, and leveraging funding.
Methods
An adapted framework guided the evaluation. Nine funded studies from 4 competitions were included. Semi-structured telephone interviews were held with researchers, stakeholders (including knowledge users), members of grant review panels, and experts in kt. Interview transcripts were audio-recorded, transcribed, and analyzed thematically. A review of proposal and report documents was also conducted.
Results
Funded researchers indicated that the grant competition was an essential funding program for cancer kt research. Competitions were perceived to build capacity in cancer kt among early-career researchers and to encourage innovative cancer kt research for which alternative funding sources are limited. The grants program resulted in incremental gains in advancing the science of kt. Suggestions to improve the program included stronger partnerships between the funder and the provincial cancer-system organization to optimize the application of research that is relevant to the organization's strategic objectives.
Conclusions
The grants program met many of its aims by providing cancer researchers with an opportunity to gain capacity in cancer kt and by making incremental advances in kt science. Suggestions to improve the program included closer partnerships between the funder and the cancer-system organization.

Identifiants

pubmed: 31548808
doi: 10.3747/co.26.5531
pii: conc-26-272
pmc: PMC6726260
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

272-284

Subventions

Organisme : CIHR
ID : FDN 143237
Pays : Canada

Déclaration de conflit d'intérêts

CONFLICT OF INTEREST DISCLOSURES We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare the following interests: MAO is the Scientific Associate for KT-Net and led the evaluation. MAO had no involvement in collecting data for the evaluation. EG is the Director for KT-Net and was a co-investigator for one of the funded studies. EG had no involvement in collecting or analyzing data for the evaluation. IDG was a co-investigator for one of the KT-Net–funded studies. IDG had no involvement in collecting or analyzing data for the evaluation. MCB was principal investigator for two of the funded studies and co-investigator for another two studies. MCB had no involvement in collecting or analyzing data for the evaluation. The remaining authors have no conflicts of interest to disclose.

Références

Implement Sci. 2011 Dec 20;6:130
pubmed: 22185329
Qual Health Res. 2005 Nov;15(9):1277-88
pubmed: 16204405
Am J Prev Med. 2012 Sep;43(3):337-50
pubmed: 22898128
Res Nurs Health. 2000 Aug;23(4):334-40
pubmed: 10940958
Implement Sci. 2014 Nov 28;9:176
pubmed: 25430813
Curr Oncol. 2014 Jun;21(3):e426-33
pubmed: 24940102
Healthc Policy. 2016 May;11(4):27-39
pubmed: 27232234
Patient Educ Couns. 2013 Oct;93(1):114-21
pubmed: 23747087
Implement Sci. 2015 Jan 08;10:4
pubmed: 25567702
Lancet. 2014 Jan 11;383(9912):101-4
pubmed: 24411643
Implement Sci. 2015 Jul 17;10:100
pubmed: 26183210
BMC Health Serv Res. 2014 Nov 19;14:545
pubmed: 25407487
Am J Gastroenterol. 2004 Jun;99(6):1141-4
pubmed: 15180738
Breast. 2013 Oct;22(5):919-25
pubmed: 23721853
J Clin Oncol. 2012 Apr 1;30(10):1095-9
pubmed: 22370317
Lancet. 2014 Jan 11;383(9912):166-75
pubmed: 24411645
Ann Fam Med. 2005 Nov-Dec;3(6):545-52
pubmed: 16338919
Curr Oncol. 2017 Apr;24(2):103-110
pubmed: 28490924
Eur J Cancer. 2016 Jul;61:85-93
pubmed: 27155447
Oncologist. 2015 Apr;20(4):351-6
pubmed: 25746345
Curr Oncol. 2014 Apr;21(2):e203-11
pubmed: 24764705
Implement Sci. 2012 Jun 22;7:57
pubmed: 22726821
Cancer Causes Control. 2004 Jun;15(5):503-10
pubmed: 15286470
J Contin Educ Health Prof. 2006 Winter;26(1):13-24
pubmed: 16557505
Milbank Q. 2016 Mar;94(1):163-214
pubmed: 26994713
JAMA. 1992 Jul 8;268(2):240-8
pubmed: 1535110
BMJ Open. 2016 Jun 02;6(6):e010981
pubmed: 27256091

Auteurs

M A O'Brien (MA)

Department of Family and Community Medicine, University of Toronto, Toronto, ON.

T Makuwaza (T)

Department of Family and Community Medicine, University of Toronto, Toronto, ON.
Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, ON.

I D Graham (ID)

School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON.
The Ottawa Hospital Research Institute, Ottawa, ON.

L Barbera (L)

Tom Baker Cancer Centre, Calgary, AB.
University of Calgary, Calgary, AB.
ices, Toronto, ON.

C C Earle (CC)

Ontario Institute for Cancer Research, Toronto, ON.

M C Brouwers (MC)

School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON.
Department of Oncology, McMaster University, Hamilton, ON.

E Grunfeld (E)

Department of Family and Community Medicine, University of Toronto, Toronto, ON.
Ontario Institute for Cancer Research, Toronto, ON.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH